Optimo Research’s latest update highlights the rapid progress made by MedPal AI (LSE:MPAL) since its IPO, with the company successfully transforming from a pre-revenue concept into a fully operational, AI-driven digital health platform. The note outlines how MedPal has built a vertically integrated model, combining digital triage, clinician-led prescribing, and automated pharmacy fulfilment, while already delivering strong early revenues and operational momentum.
With expansion into high-growth areas such as weight-loss treatments and continued investment in technology and infrastructure, the report positions MedPal as a scalable, innovation-led healthcare business with significant future potential.
Leave a Reply